Iwamoto N, Tachihara M, Ohji G. Tuberculosis with Multiserosal Dissemination. Intern Med. 2026 Feb 1. doi: 10.2169/internalmedicine.6533-25.

Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Tachihara M, Nakatani T, Harada T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Yoshizumi Y, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Mamesaya N, Misumi T, Matsutani N, Seki N.　Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.　JTO Clin Res Rep. 2026 Feb 12;7(4):100972.

Pertiwi TH, Suraya R, Akashi M, Nagano T. The Role of the Oral Microbiome in Modulating Therapeutic Outcomes in Lung Cancer: Key Commensals and Clinical Implications. Cancers (Basel). 2026 Feb 11;18(4):591.

Nagasaki T, Matsumoto H, Iwanaga T, Matsunaga K, Sekiya K, Harada T, Sakurai S, Harada N, Koya T, Fukunaga K, Kaneko T, Asai K, Komase Y, Gon Y, Tanaka A, Sagara H, Sunadome H, Nagano T, Nakamura Y, Niimi A, Hattori N, Hajiro T, Fujimoto H, Hojo M, Miyahara N, Yamaguchi M, Tsuji K, Sano A, Haraguchi R, Sano H, Muraki M, Tohda Y. Outcomes following the discontinuation of biologic therapy in patients with severe asthma. Allergol Int. 2026 Feb 4:S1323-8930(25)00152-2.

Suzuki Y, Ramadhiani R, Ryanto GRT, Musthafa A, Wardhana DA, Morimoto M, Ko CJ, Nagano T, Hara T, Yanagisawa M, Emoto N. Loss of Endothelin-2 in Pulmonary Neuroendocrine Cells Promotes the Development of Hypoxia-induced Pulmonary Hypertension. Clin Sci (Lond). 2026 Mar 3:CS20250135.

Tsugitomi R, Takagi K, Saito G, Tachihara M, Ashinuma H, Shukuya T, Takemoto S, Sakata S, Mouri A, Miwa H, Tamura Y, Tokito T, Tsukita Y, Kogure Y, Masuda T, Tanaka H, Kubo S, Sasaki T, Oba T, Mamesaya N, Yamanaka T, Nagashima H, Tamiya M, Kanemura H, Tozuka T, Furuta M, Kawachi H, Ninomiya T, Nagai Y, Ogino H, Ito K, Ishihara M, Suzuki T.　Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.　Lung Cancer. 2026 Apr;214:109309.

Kataoka S, Shukuya T, Ohtsu H, Miyawaki T, Fujimoto D, Hayashi H, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Otsubo K, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Yamamoto N, Okamoto I, Takahashi K.　Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.　Clin Lung Cancer. 2026 Apr;27(3):212-223.e10.

（総説）アレルギー用語解説シリーズ　臨床的寛解
花畑 翔子、永野 達也
アレルギー 第75巻2号 161-162 2026

Ryanto GRT, Suraya R, Nagano T. The Importance of Lung Innate Immunity During Health and Disease. Pathogens. 2025 Jan 17;14(1):91.

Suraya R, Nagano T, Tachihara M. Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities. Cancers (Basel). 2025 Feb 18;17(4):694.

Nomura N, Matsumoto H, Asano K, Hayashi Y, Yokoyama A, Nishimura Y, Hashimoto N, Sakagami T, Fukunaga K, Hizawa N, Yamasaki A, Nagase H, Hattori N, Kondo M, Harada N, Sugiura H, Miki M, Kimura T, Toyoshima M, Matsuno O, Koh H, Kita T, Tomioka H, Tomii K, Ohnishi H, Takata S, Tobino K, Imokawa S, Sunadome H, Nagasaki T, Oguma T, Tanabe N, Hirai T; BEXAS study. Refractory phenotype of Aspergillus-sensitized asthma with bronchiectasis and allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Glob. 2024 Nov 1;4(1):100364. doi: 10.1016/j.jacig.2024.100364. eCollection 2025 Feb.

Hasegawa N, Nishimura M, Takamiya R, Ishimaru H, Mori Y. SARS-CoV-2 BA.2.86 is susceptible to the neutralizing antibody MO11 targeting subdomain 1 despite the E554K mutation near the epitope. J Virol. 2025 Feb 25;99(2):e0138924.

Sato H, Nagano T, Suraya R, Hazama D, Umezawa K, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y, Emoto N, Kobayashi K. Reduction in Circulating Endothelin-1 Levels by Inhaled COPD Medications. Respir Med. 2025 Mar 3:108027.

Maria Istiqomah Marini, Rei Takamiya, Mitsuhiro Nishimura, and Yasuko Mori. Primary Infection with Early SARS-CoV-2 (D614G) Induces Cross Neutralization Antibodies against Omicron BA.5 and EG.5.1. Kobe J. Med. Sci. 2025. Apr 2; 71(1); E1-9.

Fujimoto S, Katsurada N, Hazama D, Yamamoto M, Nagano T, Tachihara M. Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease. Intern Med. 2025 64:749-751

Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, Tanaka H, Ko R, Amano Y, Tachihara　M, Suzuki T, Tanizaki J, Sugawara S, Zenke Y, Shirai Y, Hayashi T, Mori K, Takahashi K. Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 Mar 26(3):331-342.

Tanaka K, Sugisaka J, Shiraishi Y, Watanabe Y, Daga H, Azuma K, Nishino K, Mori M, Ota T, Saito H, Hata A, Sakaguchi T, Kozuki T, Akamatsu H, Matsumoto H, Tachihara M, Wakuda K, Sato Y, Ozaki T, Tsuchiya-Kawano Y, Yamamoto N, Nakagawa K, Okamoto I.Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC. Nat Commun. 2025 Mar 22;16(1):2825.

Istiqomah MM, Takamiya R, Nishimura M, Mori Y. Primary Infection with Early SARS-CoV-2 (D614G) Induces Cross Neutralization Antibodies against Omicron BA.5 and EG.5.1. Kobe J. Med. Sci. 2025. Apr 2; 71(1); E1-9.

Chen W, Tran TN, Townend J, Christoff GC, Tsai MJ, Altraja A, Cochrane B, Cosio BG, Sivori M, Murray RB, Makris MP, Scelo G, Bulathsinhala L, Ardusso LRF, Franchi ME, Máspero J, Saldarini F, Stok AM, Tomaszuk AG, Yañez A, Emmanuel B, Emmas C, Kostikas K, Menzies-Gow AN, Stjepanovic N, Bosnic-Anticevich SZ, Denton E, Gibson PG, Hew M, Jenkins C, Middleton PG, Peters MJ, Upham JW, Brusselle GG, Louis R, Schleich F, Pitrez PM, Popov TA, Bergeron C, Bhutani M, Chapman KR, Côté A, Couillard S, Dorscheid DR, Lougheed MD, Sadatsafavi M, Celis-Preciado CA, Jiménez-Maldonado L, Rodríguez-Cáceres B, Cano Rosales DJ, Solarte I, Torres-Duque CA, Hansen S, Porsbjerg CM, Ulrik CS, Bourdin A, Bakakos P, Exarchos KP, Gogali A, Ladias AA, Papadopoulos NG, Papaioannou AI, Costello RW, Cushen B, Mitchell PD, Canonica GW, Heffler E, Puggioni F, Iwanaga T, Nagano T, Tohda Y, Al-Ahmad MS, Linnemann DL, Aarli BB, Lehmann S, Kuna P, Ferreira JA, Fonseca JA, Loureiro CC, Al-Lehebi R, Bulkhi AA, Juang YR, Koh MS, Liu A, Rhee CK, Perez-de-Llano L, Fu PK, Perng DW, Sheu CC, Wang HC, Mahboub B, Salameh L, Busby J, Heaney LG, Jackson DJ, Patel PH, Pfeffer PE, Hoyte F, Katial RK, Lugogo N, Pleasants RA, Wang E, Wechsler ME, Beastall A, Carter V, Eleangovan N, Fletton K, Price DB. Impact of biologics initiation on oral corticosteroid use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: a pooled analysis of real-world data. J Allergy Clin Immunol Pract. 2025 Apr 26:S2213-2198(25)00390-3.

Nagano T, Yamamoto N, Shinomiya S, Kato H, Okamoto M, Hazama D, Bo R, Yamamura T, Imai T, Fukuzawa K, Funayama T, Kano K, Katsurada N. A noncontact vital sign sensor demonstrating a strong correlation with an electrocardiogram electrode and a CO2 sensor. Sci Rep. 2025 May 19;15(1):17269.

Schleich F, Larenas-Linnemann D, Altraja A, Pérez de Llano L, Kostikas K, Sadatsafavi M, Bourdin A, Alton Pleasants R, Hew M, Chen W, Jiménez-Maldonado L, Couillard S, Suppli Ulrik C, Bulkhi AA, Tsai MJ, Christoff GC, Papadopoulos NG, Pfeffer PE, Ryan D, Bergeron C, Al-Ahmad MS, Dorscheid DR, Wang E, Blakey JD, Cochrane B, Peters MJ, Popov TA, Torres-Duque CA, Hansen S, Puggioni F, Fletton K, Salameh L, Middleton PG, Márcio Pitrez P, Kook Rhee C, Denton E, Chapman KR, Lehtimäki L, Murray RB, Sheu CC, Jackson DJ, Al-Lehebi R, Siyue Koh M, Mahboub B, Ardusso LRF, Gogali A, Canonica GW, Kuna P, Sivori M, Louis R, Abercromby S, Guida G, Aarli BB, Beastall A, Carter V, Scelo G, Townend J, Cosio BG, Patel PH, Goh CYY, Csoma Z, Upham JW, Fonseca JA, Gibson PG, Jenkins C, Brusselle GG, Chèvremont A, Côté A, Celis-Preciado CA, Solarte I, Porsbjerg CM, Sverrild A, Kauppi P, Loukides S, Makris MP, Papaioannou AI, Heffler E, Chan JSK, Joo H, Heaney LG, Cheng WH, Lugogo N, Wechsler ME, Chaves Loureiro C, Rodríguez-Cáceres B, Nagano T, Wang Z, Wang HC, Máspero J, Saldarini F, Stok AM, Yañez A, Bardin PG, Bosnic-Anticevich SZ, Navaratnam V, Bhutani M, Lougheed MD, Melenka L, Bakakos P, Exarchos KP, Ladias AA, Lúdvíksdóttir D, Iwanaga T, Contreras EA, Lehmann S, Ferreira JA, Gall R, Fu PK, Perng DW, Hoyte F, Katial R, Björnsdóttir US, Taillé C, Taube C, Cushen B, Bulathsinhala L, Bjermer L, Price DB; ISAR STAR Working Group. Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR). World Allergy Organ J. 2025 Jun 3;18(7):101066.

Takagi K, Saito G, Tanaka H, Kubo S, Shukuya T, Tsugitomi R, Sasaki T, Oba T, Mamesaya N, Yamanaka T, Tachihara M, Gyotoku H, Nagashima H, Tamiya M, Kanemura H, Tozuka T, Furuta M, Sakata S, Mouri A, Miwa H, Kawachi H, Ninomiya T, Nagai Y, Ogino H, Ito K, Tamura Y, Tokito T, Ishihara M, Ashinuma H, Tsukita Y, Kogure Y, Masuda T, Suzuki T. Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings. ESMO Open. 2025 Jun 10(6):105301.

Yamada J, Hazama D, Fukui T, Yatani A, Okamoto M, Fujimoto S, Yoshimura R, Takayasu M, Takata N, Sato H, Mimura C, Furukawa K, Katsurada N, Yamamoto M, Tachihara M.Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study. Lung Cancer. 2025 Jun 204:108556.

Tachihara M, Shoda H, Akazawa Y, Ota T, Oki M, Sato Y, Sugawara S, Ikeda S, Yokoyama T,　 Kaneda H, Itoh S, Bessho A, Katakami N, Morita S, Nakagawa K, Okamoto I, Yamamoto N. Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L). Lung Cancer. 2025 Jun 29;206:108637.

Sadatsafavi M, Tran TN, Scelo G, Tsai MJ, Busby J, Emmanuel B, Heaney LG, Jenkins C, Hoyte F, Canonica GW, Katial R, Heffler E, Wang E, Puggioni F, Wechsler ME, Ardusso LRF, Máspero J, Sivori M, Emmas C, Menzies-Gow AN, Stjepanovic N, Bosnic-Anticevich SZ, Cochrane B, Denton E, Gibson PG, Hew M, Middleton PG, Peters MJ, Brusselle GG, Louis R, Schleich F, Christoff GC, Popov TA, Bergeron C, Bhutani M, Chapman KR, Côté A, Couillard S, Dorscheid DR, Jiménez-Maldonado L, Solarte I, Torres-Duque CA, Hansen S, Porsbjerg CM, Ulrik CS, Altraja A, Bourdin A, Exarchos KP, Gogali A, Kostikas K, Makris MP, Papaioannou AI, Mitchell PD, Iwanaga T, Nagano T, Tohda Y, Al-Ahmad MS, Larenas-Linnemann D, Aarli BB, Kuna P, Chaves Loureiro C, Al-Lehebi R, Bulkhi AA, Chen W, Juang YR, Koh MS, Liu A, Rhee CK, Cosio BG, Perez-de-Llano L, Perng DW, Sheu CC, Wang HC, Mahboub B, Salameh L, Jackson DJ, Patel PH, Pfeffer PE, Lugogo N, Pleasants RA, Beastall A, Bulathsinhala L, Carter V, Eleangovan N, Fletton K, Townend J, Murray RB, Price DB. Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. Am J Respir Crit Care Med. 2025 Jul 211(7):1165-1174.

Matsumoto H, Kanemitsu Y, Ohe M, Tanaka H, Terada K, Nishi K, Atsuta R, Hara J, Saito J, Ohmichi M, Ishizuka T, Nishiuma T, Inoue H, Watanabe N, Nagano T, Ueda T, Ogawa H, Endo S, Suzuki T, Kita T, Fujimori K, Ishiura Y, Fujimura M, Niimi A. Real-world usage and response to gefapixant in refractory chronic cough. ERJ Open Res. 2025 Jul 7;11(4):01037-2024.

Nagano T. Robust evidence of the rapid efficacy of benralizumab. J Thorac Dis. 2025 Jul 31;17(7):4376-4378.

Wang E, Henley W, Larenas-Linnemann D, Bulathsinhala L, Tran TN, Wechsler ME, Aaron SD, Al-Ahmad M, Al-Lehebi R, Altraja A, Barker P, Beastall A, Belevskiy AS, Bergeron C, Bjermer L, Björnsdóttir US, Bosnic-Anticevich SZ, Bourdin A, Brusselle GG, Busby J, Canonica GW, Carter V, Chapman KR, Chapman N, Christoff GC, Cosio BG, Costello RW, Fingleton J, Ioa Fonseca JA, Gaga M, Gibson PG, Hansen S, Heaney LG, Heffler E, Hew M, Horiguchi T, Hoyte F, Hubbard RB, Iwanaga T, Jackson DJ, Katial R, Koh MS, Kostikas K, Kuna P, Lehmann S, Lehtimäki L, Louis R, Lúdvíksdóttir D, Lugogo N, Mahboub B, Martin N, Máspero J, Menzies-Gow AN, Mohan A, Murray RB, Nagano T, Papadopoulos NG, Papaioannou AI, Patel PH, Perez-de-Llano L, Perng DW, Peters MJ, Pfeffer PE, Pitrez PM, Pleasants RA, Popov TA, Porsbjerg CM, Puggioni F, Quinton A, Rhee CK, Sadatsafavi M, Salvi S, Scioscia G, Sheu CC, Sirena C, Taillé C, Taube C, Torres-Duque CA, Tsai MJ, Tunsäter A, Ulrik CS, Price DB. Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach. J Allergy Clin Immunol Pract. 2025 Sep 1:S2213-2198(25)00822-0.

Fukui T, Hori S, Hatakeyama Y, Kiriu T, Matsumura K, Miwa N, Katsurada M, Okuno K, Yoshimura S, Tachihara M. Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy. Anticancer Res. 2025 Sep 45(9):3859-3875.

Shiraishi Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, Morinaga R, Inoue H, Toi Y, Yamada T, Yamaguchi M, Kashiwabara K, Tobino K, Ishii H, Sakata Y, Inaba M, Nakashima K, Chibana K, Fukui T, Izumi M, Saito R, Ishii H, Omori S, Ogusu S, Furuyama K, Miura S, Harada T, Okamoto I. Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102). Eur J Cancer. 2025 Oct 16;229:115779.

Takayasu M, Katsurada N, Yamamoto M, Izumi S, Yoshizaki A, Matsumura K, Nagano T. Investigation of the Usefulness of Waveform Classification Analysis of Oxygen Saturation for Sleep Apnea Syndrome. In Vivo. 2025 Nov-Dec 39(6):3484-3490.

Shirai T, Kakei Y, Muraki Y, Nagano T, Suraya R, Uryu K, Takeda D, Shigeoka M, Kimoto A, Hasegawa T, Hara T, Emoto N, Akashi M. Expression Analysis of JCAD and IL-33 in Gingival Cancer Tumor Angiogenesis. Cancers (Basel). 2025 Nov 21;17(23):3732.

Kataoka S, Shukuya T, Ohtsu H, Miyawaki T, Fujimoto D, Hayashi H, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Otsubo K, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Yamamoto N, Okamoto I, Takahashi K.　Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.　Clin Lung Cancer. 2025 Dec 9:S1525-7304(25)00330-4.

Mihashi Y, Komuta K, Tsukaguchi A, Inada R, Yanagisawa A, Shimizu Y, Yamamoto K, Tanaka S, Katsurada N, Nakatani T, Takeyasu Y, Otsuki T, Tetsumoto S, Tamiya A, Shiroyama T, Tachihara M, Nishino K, Kurata T, Mori M. Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan. Invest New Drugs. 2025 Dec 43(6):1201-1210

Uza M, Kang D, Kajino M, Chuang HC, Nagano T, Fujitani Y, Hsiao TC, Lin NH, Xuân TN, Shimada K. Development of a Data Analysis and Visualization Platform for Elucidating the Relationship Between Air Pollution and Disease Onset. The 32nd ICAST 2025.

Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N. Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). Ther Adv Med Oncol. 2025 17:17588359251344010.

（総説）知れば納得！COPD治療の必要性
吉村遼佑, 永野達也
西宮市医師会医学雑誌, 第30号 1-2, 2025年

（書籍）細胞障害性抗がん薬＋TRT→Durvalumab(地固め療法)
立原 素子
肺がん薬物療法副作用マネージメント 改訂第2版 MEDICAL VIEW社 2025

Ohnishi H, Otani T, Kanemitsu Y, Nagano T, Hara J, Eitoku M. A systematic review and meta-analysis of macrolides in the management of adult patients with asthma. Allergol Int. 2024 Jan 30:S1323-8930(24)00003-0.

Mimura C, Nagano T, Miwa N, Matsumura K, Yamada J, Satoh H, Suraya R, Hazama D, Tamura D, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K. Mechanism of action of adapalene for treating EGFR-TKI-induced skin disorder. Thorac Cancer. 2024 15(9):722-729.

Ishiura Y, Fujimura M, Ogawa H, Hara J, Shintani H, Hozawa S, Atsuta R, Fukumitsu K, Inoue H, Shioya T, Muraki M, Amemiya T, Ohkura N, Oribe Y, Tanaka H, Yamada T, Toyoshima M, Fujimori K, Ishizuka T, Kagaya M, Suzuki T, Kita T, Nishi K, Ueda A, Miyata Y, Kitada J, Yamamura K, Abo M, Takeda N, Shirai T, Tajiri T, Yoshihara S, Akamatsu T, Sawaguchi H, Nagano T, Hanada S, Masuda S, Ohmichi M, Ito T, Sagara H, Matsumoto H, Niimi A; Japan Cough Society. Prevalence and causes of chronic cough in Japan. Respir Investig. 2024 Mar 22;62(3):442-448.

Yoshioka J, Nagano T, Sekiya R, Mimura C, Satoh H, Otoshi T, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K. Effects of Tongue Strength Training on Patients with Mild to Moderate Sleep-disordered Breathing: A Randomized Controlled Trial. Prog Rehabil Med. 2024 Mar 23;9:20240010.

Yamaguchi M, Nishimura Y, Takumi Y, Hayashi N, Sakamoto K, Tohda Y. Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study.J Asthma Allergy. 2024 17:45-60.

Tanabe N, Kumamaru H, Tamura Y, Kondoh Y, Nakayama K, Kinukawa N, Kimura T, Nishiyama O, Tsujino I, Shigeta A, Morio Y, Inoue Y, Kuraishi H, Hirata K, Tanaka K, Kuwana M, Nagaoka T, Handa T, Sugimura K, Sakamaki F, Naito A, Taniguchi Y, Matsubara H, Hanaoka M, Inami T, Hayama N, Nishimura Y, Kimura H, Miyata H, Tatsumi K. Pulmonary Hypertension With Interstitial Pneumonia: Initial Treatment Effectiveness and Severity in a Japan Registry.JACC ASIA.2024 Mar 26;4(5):403-417.

Yamada J, Fukui T, Yatani A, Mimura C, Fukuda K, Hazama D, Katsurada N, Nagano T, Yamamoto M, Tachihara M. Impact of concurrent medications on the outcome of immunotherapy in non-small cell lung carcinoma. Thorac Cancer. 2024 Apr 15(15):1228-1236.

Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Ławkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, Price DB. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024 Apr 19;15:1361891.

Ishimaru H, Nishimura M, Shigematsu H, Marini MI, Hasegawa N, Takamiya R, Iwata S, Mori Y. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein. J Virol. 2024 May 14;98(5):e0041624.

Tachihara M, Tsujino K. Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer-Reply. JAMA Oncol. 2024 Jun 1;10(6):829-830.

Sato H, Nagano T, Izumi S, Yamada J, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K. Prospective observational study of 2 wearable strain sensors for measuring the respiratory rate. Medicine (Baltimore). 2024 Jul 19;103(29):e38818.

Fujimoto S, Katsurada N, Hazama D, Yamamoto M, Nagano T, Tachihara M. Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease: A Case Report. Intern Med. 2024 Jul 25. doi: 10.2169/internalmedicine.3932-24.

Taniguchi N, Kawaguchi H, Nagano T, Izumi S. Sleep Apnea Detection Using Oxygen Saturation During Nocturnal Sleep. Annu Int Conf IEEE Eng Med Biol Soc. 2024 Jul 2024:1-4.

Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. Lung Cancer. 2024 Jul 193:107852.

Nagano T, Suraya R, Yumura M, Hara T, Akashi M, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K. Loss of JCAD/KIAA1462 Protects the Lung from Acute and Chronic Consequences of Chronic Obstructive Pulmonary Disease. Int J Mol Sci. 2024 Aug 31;25(17):9492.

Suraya R, Nagano T, Yumura M, Hara T, Akashi M, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K. Loss of JCAD/KIAA1462 Protects the Lung from Acute and Chronic Consequences of Chronic Obstructive Pulmonary Disease. Int J Mol Sci. 2024 Aug 31;25(17):9492.

Fujimoto D, Hayashi H, Murotani K, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Shukuya T, Tsuchiya-Kawano Y, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Otsubo K, Shibaki R, Makino M, Okamoto I, Yamamoto N. Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND). Lung Cancer. 2024 Aug;194:107896.

Yatani A, Nagano T, Murakami S, Otoshi T, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K. Randomized crossover trial of a demand oxygen delivery system in nocturnal hypoxemia. Sci Rep. 2024 Sep 3;14(1):20505.

Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, Sugasaki N, Nakatomi K, Kiyomi F, Okamoto I. Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004). Eur J Cancer. 2024 Sep 29;212:115052.

Nagano T, Hashimoto M, Izumi S, Hata Y, Tsuji M, Morota K, Hata A, Kobayashi K. Effect of 10-minute oropharyngeal exercise on the apnoea-hypopnoea index. Sci Rep. 2024 Nov 19;14(1):28645.

Effendi GB, Aoki K, Marini MI, Takamiya R, Ishimaru H, Nishimura M, Mori Y. Single Amino Acid Substitution Within the Helicase of Varicella Zoster Virus Makes It Resistant to Amenamevir. J Med Virol. 2024 Nov;96(11):e70080.

Nagano T. Biologics treatment for eosinophilic chronic rhinosinusitis complicated by bronchial asthma: Narrative review. Respir Investig. 2024 Dec 2;63(1):35-39.

Ishiura Y, Fujimura M, Ogawa H, Hara J, Shintani H, Hozawa S, Atsuta R, Fukumitsu K, Inoue H, Shioya T, Muraki M, Amemiya T, Ohkura N, Oribe Y, Tanaka H, Yamada T, Toyoshima M, Fujimori K, Ishizuka T, Kagaya M, Suzuki T, Kita T, Nishi K, Ueda A, Miyata Y, Kitada J, Yamamura K, Abo M, Takeda N, Shirai T, Tajiri T, Yoshihara S, Akamatsu T, Sawaguchi H, Nagano T, Hanada S, Masuda S, Ohmichi M, Ito T, Sagara H, Matsumoto H, Niimi A; Japan cough Society. Prevalence and causes of subacute cough in Japan. Respir Investig. 2024 Dec 6;63(1):74-80.

Katsurada N, Tachihara M. Locally advanced non-small cell lung cancer: search for the optimal radiotherapy continues. Transl Cancer Res. 2024;13:6603-6607.

（総説）アレルギー用語解説シリーズ　ビタミンAと免疫の関連
平位一廣, 永野達也
アレルギー, 第73巻2号, 1-2, 2024年

（総説）咳と喘息治療の最前線　～耳鼻科の先生にお伝えしたいこと～
吉村遼佑, 永野達也
耳鼻咽喉科奈良, 第43巻1号, 16-19, 2024年

（総説）希少肺疾患はどこまで解明されたか　肺胞微石症
吉村将，永野達也，吉村遼佑，増田佳純，髙安みずき，畠山由記久，羽間大祐，桂田直子，山本正嗣，立原素子，大西尚，西村善博，小林和幸
呼吸器内科, 45(4), 1-4, 2024年

（総説）肺のう胞（ブラ）の疑いを指摘された。肺がんになる可能性はある？
永野達也
すこやかファミリー, 8月号, 2024年

（総説）アレルギー用語解説シリーズ　レジデントメモリーB細胞
木田菜々美, 永野達也
アレルギー, 第73巻10号, 1219, 2024年

（総説）【睡眠関連呼吸障害の呼吸器的新展開】特発性肺線維症と睡眠関連呼吸障害
高原夕, 永野達也
呼吸器内科, 46(5), 470-471, 2024年

（書籍）気管支鏡検査の正確性向上のために
立原 素子
インナービジョン 2024.11月号 医療と画像の総合情報誌 C-02-05 2024

Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung Cancer. 2023 177:44-50.

Tanda M, Yamamoto K, Hori T, Nishiguchi H, Yagi M, Shimizu M, Konishi T, Ozaki T, Yoshioka N, Tachihara M, Ito T, Ikushima S, Omura T, Yano I. Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Res. 2023 43:1775-1783.

Okamoto T, Murata Y, Hasegawa D, Yoshida M, Tanaka D, Ueda T, Hazama D, Oduori OS, Komori S, Takai T, Saito Y, Kotani T, Kosaka Y, Maniwa Y, Matozaki T.Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis.Cancer Sci. 2023 Feb 14. doi: 10.1111/cas.15758. Online ahead of print.

Ishimaru H, Nishimura M, Tjan LH, Sutandhio S, Marini MI, Effendi GB, Shigematsu H, Kato K, Hasegawa N, Aoki K, Kurahashi Y, Furukawa K, Shinohara M, Nakamura T, Arii J, Nagano T, Nakamura S, Sano S, Iwata S, Okamura S, Mori Y. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants. J Virol. 2023 May 16:e0028623.

Sutandhio S, Furukawa K, Kurahashi Y, Marini MI, Effendi GB, Ishimaru H, Hasegawa N, Ishimaru H, Nishimura M, Arii J, Mori Y. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population. J Infect Public Health. 2023 Jul;16(7):1064-1072.

Yamada J, Katsurada N, Yamamoto M, Sato H, Mimura C, Yoshioka J, Yumura M, Hazama D, Nagano T, Tachihara M, Nishimura Y, Kobayashi K.In-hospital Mortality among Patients with High-flow Nasal Cannulas in the General Ward.Kobe J Med Sci. 2023; 69(1): E33-E39.

Sekiya R, Nagano T, Moriyama T, Kawaguchi A, Fukui T, Mimura C, Kimura Y, Ohnishi H, Kotani Y, Nishimura Y. A case of eosinophilic pneumonia induced by lettuce. Respirol Case Rep. 2023 May 25;11(6):e01169

Ryanto GRT, Suraya R, Nagano T. Mitochondrial Dysfunction in Pulmonary Hypertension. Antioxidants (Basel). 2023 Feb 3;12(2):372.

Effendi WI, Nagano T. A2B Adenosine Receptor in Idiopathic Pulmonary Fibrosis: Pursuing Proper Pit Stop to Interfere with Disease Progression. Int J Mol Sci. 2023 Feb 23;24(5):4428.

Effendi WI, Nagano T. Epigenetics Approaches toward Precision Medicine for Idiopathic Pulmonary Fibrosis: Focus on DNA Methylation. Biomedicines. 2023 Mar 28;11(4):1047.

Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial. Clin Lung Cancer. 2023 Jun 3:S1525-7304(23)00110-9.

Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, Ko R, Zenke Y, Akamatsu H, Tanizaki J, Ikeda S, Sugawara S, Mizutani H, Mori K, Takahashi K. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). Clin Lung Cancer. 2023 May 19:S1525-7304(23)00099-2.

Nagano T, Miyata Y, Suzuki K, Iida K, Hasegawa T, Uga H, Matsuoka H. Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan. Sci Rep. 2023 Jul 8;13(1):11071.

Enomoto Y, Katsura H, Fujimura T, Ogata A, Baba S, Yamaoka A, Kihara M, Abe T, Nishimura O, Kadota M, Hazama D, Tanaka Y, Maniwa Y, Nagano T, Morimoto M. Autocrine TGF-β-positive feedback in profibrotic AT2-lineage cells plays a crucial role in non-inflammatory lung fibrogenesis. Nat Commun. 2023 Aug 31;14(1):4956.

Tachihara M, Hata A, Tokito T, Hara S, Okada H, Miura S, Sato Y, Tabata E, Watanabe H, Takayama Y, Toyozawa R, Ota K, Wakuda K, Nakamura A, Shimokawa M, Yamamoto N, Nakagawa K.　Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).JTO Clin Res Rep. 2023 Aug 23;4(10):100569

Fukuda K, Katsurada N, Kawa Y, Satouchi M, Kaneshiro K, Matsumoto M, Takamiya R, Hatakeyama Y, Dokuni R, Matsumura K, Katsurada M, Nakata K, Yoshimura S, Tachihara M. Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer. Heliyon. 2023 Sep 26;9(10): e20463.

Musthafa A, Ryanto GRT, Suraya R, Nagano T, Suzuki Y, Hara T, Hirata KI, Emoto N. Acute Amelioration of Inflammatory Activity Caused by Endothelin-2 Deficiency during Acute Lung Injury. Kobe J Med Sci. 2023 Oct 24;69(3):E96-E105.

Hazama D, Nakahama K, Kodama H, Miyazaki A, Azuma K, Kawashima Y, Sato Y, Ito K, Shiraishi Y, Miura K, Takahama T, Oizumi S, Namba Y, Ikeda S, Yoshioka H, Tsuya A, Yasuda Y, Negi Y, Hara A, Toda M, Tachihara M. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. JTO Clin Res Rep. 2023 Nov 27;5(1):100613.

Yoshioka J, Nagano T, Sekiya R, Yano E, Hatano N, Katsurada N, Yamamoto M, Tachihara M, Uno Y, Moriyama T, Nishimura Y, Kobayashi K. Identification of a 17 kDa protein that is a potentially novel antigen of lettuce-associated respiratory allergy in farmers. Immun Inflamm Dis. 2023 Nov;11(11):e1093.

Ogimoto A, Katsurada N, Yatani A, Mimura C, Yamamoto M, Tachihara M. HIP1-ALK-Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report. JTO Clin Res Rep. 2023 Nov 25;5(1):100612.

Urai S, Watanabe M, Bando H, Motomura Y, Yamamoto M, Tachihara M, Kanzawa M, Fukuoka H, Iguchi G, Ogawa W. Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody. Front Immunol. 2023 Nov 14;14:1284301.

Saito Y, Iida-Norita R, Afroj T, Refaat A, Hazama D, Komori S, Ohata S, Takai T, Oduori OS, Kotani T, Funakoshi Y, Koma YI, Murata Y, Yakushijin K, Matsuoka H, Minami H, Yokozaki H, Manz MG, Matozaki T. Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models. Front Immunol. 2023 Dec 14;14:1294814.

Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L. Cancer Med. 2023 Dec;12(23):21097-21110.

Katsurada N, Tsukamoto S, Yamamoto M, Fujimoto S, Masuda A. Postmortem Diagnosis of Gallbladder Cancer Presenting as Pulmonary Lymphangitic Carcinomatosis With Concurrent Gallbladder Adenomyomatosis. Cureus. 2023 Dec 5;15(12):e49988.

Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol. 2023 Dec 21:e235258.

Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023 1;6(12):e2347700.

Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K. West Japan Oncology Group (WJOG).　Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023 9(11):1505-1513

Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K, Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, Tanizaki J, Imai T, Nogami S, Yamamoto N, Nakagawa K, Hattori N. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. Sci Rep. 2023 13(1):19729

Wakuda K, Kenmotsu H, Sato Y, Nakamura A, Akamatsu H, Tachihara M, Miura S, Yokoyama T, Mori K, Nakagawa K, Yamamoto N. Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L). BMC Cancer. 2023 23(1):902

経気管支肺クライオ生検により診断したdiffuse pulmonary meningotheliomatosisの1例
藤本昌大，立原素子，桂田直子，田中伴典，山田潤，佐藤宏紀，羽間大祐，山本正嗣，小林和幸
気管支学, 46 (2) :85-89, 2024

（総説）高齢の父が間質性肺炎と診断. ステロイドの長期使用が心配
永野達也
Health&Life. 1月号, 20, 2023年

（総説）肺がん診療のエッセンス
永野達也, 眞庭謙昌
ING vol.29, 22-23, 2023年

（総説）睡眠時無呼吸症候群
永野達也
Pulse vol.41, 8-9, 2023年

（総説）乾燥の季節、気になる咳にご注意。長引く咳は隠れた病気が潜んでいるかも！？
永野達也
神戸新聞記者クラブ　奥さま手帳, 18-19, 2023年

（書籍）特集Ⅱ　本邦におけるCOVID-19ワクチン　BNT162b2 mRNA COVID-19ワクチン後のSARS-CoV-2変異株に対する中和抗体応答
古川皓一
臨床免疫・アレルギー科　第79巻第1号（通巻631号）　科学評論社　2023年1月25日発行

（書籍）過敏性肺炎
西村善博
今日の治療指針2023　福井次矢、高木誠、小室一成編　医学書院　314-315, 2023

（書籍）喘息の発症メカニズムと治療・管理
永野達也, 西村善博, 医師薬出版, 4-7, 2023年

（書籍）コンパクトなＣアームＸ選TVシステムによる高画質・低被ばくな検査環境が呼吸器内科の高精度な手技と安全性に寄与する
立原 素子
インナービジョン 2023.6月号 医療と画像の総合情報誌 64-65 2023

Yasuda Y, Nagano T, Jimbo N, Kiriu T, Suraya R, Hazama D, Yamamoto M, Maniwa Y, Nishimura Y, Kobayashi K. Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma. Anticancer Res. 2022; 42:271-277.

Nakajima T, Nagano T, Nishiuma T, Nakata K, Nishimura Y. Usefulness Analysis of Fraction of Exhaled Nitric Oxide for the Differential Diagnosis of Acute Cough. In Vivo. 2022; 36:446-449.

Yumura M, Nagano T, Jimbo N, Dokuni R, Kiriu T, Tanaka Y, Tachihara M, Itoh T, Maniwa Y, Nishimura Y, Kobayashi K. Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma. Anticancer Res. 2022 42:1289-1294.

Otoshi T, Nagano T, Park J, Hosomi K, Yamashita T, Tachihara M, Tabata T, Sekiya R, Tanaka Y, Kobayashi K, Mizuguchi K, Itoh T, Maniwa Y, Kunisawa J, Nishimura Y. The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma. Anticancer Res. 2022 42:1589-1598

Nakajima T, Nagano T, Nishimura Y. Retrospective Analysis of the Starting Dose of Combined ICS/LABA for Cough-variant Asthma and Cough-predominant Asthma. In Vivo. 2022 36:949-953

Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers (Basel). 2022 14:1184

Oizumi S, Takamura K, Harada T, Tachihara M, Morikawa N, Honda R, Watanabe S, Asao T, Kunisaki M, Fukuhara T, Noro R, Kikuchi E, Tsutani Y, Tenma T, Kobayashi K, Dosaka-Akita H; North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group. Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024Int J Clin Oncol. 2022 27:676-683.

Kurahashi Y, Sutandhio S, Furukawa, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. Front Immunol. 2022 Feb 24;13:773652.

Sakamoto M, Murata Y, Tanaka D, Kakuchi Y, Okamoto T, Hazama D, Saito Y, Kotani T, Ohnishi H, Miyasaka M, Fujisawa M, Matozaki T., Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages. Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):e2109923118.

Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination. J Infect Dis. 2022 May 5:jiac178. doi: 10.1093/infdis/jiac178.

Katsurada M, Tachihara M, Katsurada N, Takata N, Sato H, Mimura C, Yoshioka J, Furukawa K, Yumura M, Otoshi T, Yasuda Y, Kiriu T, Hazama D, Nagano T, Yamamoto M, Nishimura Y, Kobayashi K. Randomized single-blind comparative study of the midazolam/pethidine combination and midazolam alone during bronchoscopy. BMC Cancer. 2022 22:539.

Suprapto RP, Suzuki Y, Nagano T, Hirata KI, Emoto N. The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line. Can J Physiol Pharmacol. 2022 Jun 9. doi: 10.1139/cjpp-2022-0006.

Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Yamaguchi F, Breadner D, Nagano T, Tanaka F, Husain H, Li K, Han B. The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study. Transl Lung Cancer Res. 2022 11:776-785.

Suraya R, Nagano T, Ryanto GRT, Effendi WI, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Emoto N, Nishimura Y, Kobayashi K. Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation. Respir Res. 2022 23: 173.

Bao M, Huang Y, Lang Z, Zhao H, Saito Y, Nagano T, Kawagoe I, Divisi D, Hu X, Jiang G. Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer. Transl Lung Cancer Res. 2022 11:1434-1452.

Nakajima T, Nagano T, Miyata Y, Murakami S, Mitsuyuki S, Funakoshi Y, Yakushijin K, Horimoto H, Nishimura Y, Kobayashi K. Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients. Allergy Asthma Clin Immunol. 2022 18:78.

Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers (Basel). 2022 14:1184

Effendi WI, Nagano T. Connective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge. Int J Mol Sci. 2022 23:6064

Suraya R, Tachihara M, Nagano T, Nishimura Y, Kobayashi K. Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. Cancer Manag Res. 2022 14:2079-2090.

Nagano T, Tachihara M, Tanaka Y. Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer. J Thorac Dis. 2022 14:809-811.

Tjan LH, Furukawa K, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y. Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster Vaccination. J Infect Dis. 2022 Apr 28;jiac159

Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y. Assessment of neutralizing antibody response against SARS-CoV-2 variants after 2 to 3 doses of the BNT162b2 mRNA COVID-19 vaccine.
JAMA Network Open. 2022 May 2;5(5):e2210780

Ren Z, Nishimura M, Tjan LH, Furukawa K, Kurahashi Y, Sutandhio S, Aoki K, Hasegawa N, Arii J, Uto K, Matsui K, Sato I, Saegusa J, Godai N, Takeshita K, Yamamoto M, Nagashima T, Mori Y. Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron’s outbreak. PLoS One. 2022 Apr 5;17(4):e0266270

Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination. J Infect Dis. 2022 May 5;jiac178

Furukawa K, Kurahashi Y, Ishimaru H, Nishimura M, Arii J, Sano S, Tohma Y, Ohkita H, Nakamura S, Iwata S, Mori Y. The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron variant. J Infect Dis. 2022 Sep 26;jiac395

Takemura T, Kataoka Y, Ashi N, Shirakawa C, Okazaki K, Sakurai A, Imakita T, Ikegaki S, Matsumoto H, Saito E, Takata H, Kaku S, Wada N, Shinomiya M, Otoshi T, Shimada M, Nikaido J, Iki R, Hirano K, Hirai T, Endo K, Hirabayashi M, Naganuma T. Influence of social isolation and loneliness on the prognosis of advanced lung cancer patients: a prospective cohort study. Support Care Cancer. 2022 Jul;30:6045-6053

Ishimaru H, Nishimura M, Tjan LH, Sutandhio S, Marini MI, Effendi GB, Shigematsu H, Kato K, Hasegawa N, Aoki K, Kurahashi Y, Furukawa K, Shinohara M, Nakamura T, Arii J, Nagano T, Nakamura S, Sano S, Iwata S, Mori Y.Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75. bioRxiv (preprint) doi: https://doi.org/10.1101/2022.09.02.506305

Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K. A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Cancer Res. 2022 28:893-902.

Nishikubo M, Jimbo N, Tanaka Y, Tachihara M, Itoh T, Maniwa Y. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma? Virchows Arch. 2022 481:307-312.

Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L) Lung Cancer. 2022 168:38-45.

Shimizu N, Tanaka Y, Tachihara M, Maniwa Y. ROS1-Rearranged Lung Cancer Successfully Resected after Response to Crizotinib: A Case Report. Kobe J Med Sci. 2022 67:E143-E145.

Bao M, Huang Y, Lang Z, Zhao H, Saito Y, Nagano T, Kawagoe I, Divisi D, Hu X, Jiang G. Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer. Transl Lung Cancer Res. 2022 Jul;11:1434-1452.

Nakajima T, Nagano T, Miyata Y, Murakami S, Mitsuyuki S, Funakoshi Y, Yakushijin K, Horimoto H, Nishimura Y, Kobayashi K. Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients. Allergy Asthma Clin Immunol. 2022 Aug 25;18:78.

Katsurada N, Nagano T, Yamamoto M, Kiriu T, Dokuni R, Kamiryo H, Yoshioka A, Fukunaga A, Nishigori C, Nishimura Y, Kobayashi K. Cross-sectional study of cholinergic urticaria subtypes and bronchial hyperresponsiveness. Sci Rep. 2022 Oct 27;12:18122.

Mimura C, Kaneshiro K, Fujimoto S, Dokuni R, Iwamoto N, Matsumura K, Hatakeyama Y, Kono Y, Tachihara M. TAPO in first-line osimertinib therapy and continuation of Osimertinib. Thorac Cancer. 2023;14:584-591.

Yamada J, Hazama D, Tachihara M, Kawanami Y, Kawaguchi A, Yatani A, Sato H, Mimura C, Katsurada N, Yamamoto M, Nishimura Y, Kobayashi Y. The utility of bispectral index monitoring in flexible bronchoscopy: A single-center, retrospective observational study. Thorac Cancer. 2022; 13: 3052-3057.

Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, Kanemaru R, Watanabe K, Ninomiya K, Aragane N, Yanagitani N, Sakata Y, Seike M, Fujimoto D, Kasajima M, Kubo A, Kusumoto S, Oyamada Y, Fujiwara K, Mori M, Hashimoto M, Shingyoji M, Kodani M, Sakamoto J, Agatsuma T, Kashiwabara K, Inomata M, Tachihara M, Tanaka K, Hayashihara K, Koyama N, Matsui K, Minato K, Jingu D, Sakashita H, Hara S, Naito T, Okada A, Tanahashi M, Sato Y, Asano K, Takeda T, Nakazawa K, Harada T, Shibata K, Kato T, Miyaoka E, Yoshino I, Gemma A, Mitsudomi T. Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data. JTO Clin Res Rep. 2022 3:100404.

Nomura N, Matsumoto H, Yokoyama A, Nishimura Y, Asano K, Niimi A, Tohda Y, Harada N, Nagase H, Nagata M, Inoue H, Kondo M, Horiguchi T, Miyahara N, Hizawa N, Hojo M, Hattori N, Hashimoto N, Yamasaki A, Kadowaki T, Kimura T, Miki M, Taniguchi H, Toyoshima M, Kawamura T, Matsuno O, Sato Y, Sunadome H, Nagasaki T, Oguma T, Hirai T; BEXAS study.　Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes. Respir Res. 2022 ;23:365.

Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination J Infect Dis. 2022 May 5:jiac178.

1年間経過した魚骨を全身麻酔下で摘出した気管支異物の1例
矢谷敦彦，黒田栞，山本正嗣，立原素子，山田潤，羽間大祐，桂田直子，松村考，清水奈保子，西村善博
気管支学, 44(1): 50-53, 2022

クロピドグレルによる薬剤誘発性ループスの1例
高宮麗，岡村佳代子，塚本玲，松尾健二郎，池田美穂，大西尚
日呼吸誌, 11(4): 207-211, 2022

(総説)毎年冬に必ず出るせき
永野達也
Health＆Life　2022年1月号

（総説）【喘息の発症メカニズムと治療・管理】疫学、遺伝、発症予防　喘息の疫学
永野 達也, 西村 善博
医学のあゆみ2022年281巻1号 Page4-7

（総説）アレルギー用語解説シリーズ　Airway epithelial basal cell
佐藤 宏紀, 永野 達也, 西村 善博
アレルギー2022年71巻3号 Page254-255

（総説）【難治性慢性咳嗽治療の新展開-ゲーファピキサントへの期待-】原因疾患別の診断と治療　最新のガイドラインを踏まえて　喘息/咳喘息
永野 達也, 西村 善博
Progress in Medicine 2022年42巻6号 Page541-544

（総説）アレルギー用語解説シリーズ　腸内細菌叢とアレルギー
安井 裕美, 永野 達也, 西村 善博
日本喘息学会誌　1 (1), 46-48, 2022年

（総説）長時間作用性抗コリン薬（LAMA）
永野達也，西村善博
Health＆Life　2022年1月号

（総説）呼吸器領域におけるがんゲノム医療
永野達也, 國政啓, 眞庭謙昌
日本気管食道科学会　専門医通信　第65号, 17-21, 2022年

Tjan LH, Nagano T, Furukawa K, Nishimura M, Arii J, Fujinaka S, Iwata S, Sano S, Tohma Y, Nishimura Y, Mori Y. The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients. JMA J. 2021 Jan 29; 4(1): 1–7.

Tjan LH, Furukawa K, Nagano T, Kiriu T, Nishimura M, Arii J, Hino Y, Iwata S, Nishimura Y, Mori Y. Early differences in cytokine production distinguish severity of COVID-19. J Infect Dis. 2021 Apr 8;223(7):1145-1149

Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(3):386-394.

Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Kogure Y, Tachihara M, Fujimoto D, Yamaguchi K, Hamaguchi N, Okamoto I, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L) Clin Lung Cancer. 2021 Jan 25:S1525-7304(20)30352-1.

Furukawa K, Arii J, Nishimura M, Tjan LH, Lystia Poetranto A, Ren Z, Aktar S, Huang JR, Sutandhio S, Kurahashi Y, Nishino A, Shigekuni S, Takeda Y, Uto K, Matsui K, Sato I, Inui Y, Endo K, Kosaka Y, Oota T, Saegusa J, Mori Y. Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. JMA J. 2021 Jan 29; 4(1): 41-49.

Suraya R, Nagano T, Katsurada M, Sekiya R, Kobayashi K, Nishimura Y. Molecular mechanism of asthma and its novel molecular target therapeutic agent. Respir Investig. 2021 May;59(3):291-301.

Yoshizaki A, Nagano T, Izumi S, Funada Y, Nakata K, Nishiuma T, Takatsuki K, Ohnishi H, Hazeki N, Yasuda Y, Dokuni R, Yamamoto M, Kobayashi K, Nishimura Y. Prospective Study of Nocturnal Desaturation in Patients Receiving Home Oxygen Therapy. Internal Medicine. 2021 Oct 1; 60 (19):3071-3079.

Mimura C, Tachihara M, Kusuhara S, Fukuoka H, Nishimura Y Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis. Respirol Case Rep. 2021 Apri;9(4): e00730

Zenke Y, Tsuboi M, Chiba Y, Tsujino K, Satouchi M, Sawa K, Shimizu J, Daga H, Fujimoto D, Mori M, Aoki T, Sawa T, Omori S, Saka H, Iwamoto Y, Okuno M, Hirashima T, Kashiwabara K, Tachihara M, Ymamoto N, Nakagawa K. Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Mar 18;7(6):904-909.

Tanabe N, Kumamaru H, Tamura Y, Taniguchi H, Emoto N, Yamada Y, Nishiyama O, Tsujino I, Kuraishi H, Nishimura Y, Kimura H, Inoue Y, Morio Y, Nakatsumi Y, Satoh T, Hanaoka M, Kusaka K, Sumitani M, Handa T, Sakao S, Kimura T, Kondoh Y, Nakayama K, Tanaka K, Ohira H, Nishimura M, Miyata H, Tatsumi K; JRPHS Group. Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circ J. 2021 Mar 25;85(4):333-342.

Kim KW, Kusuhara S, Tachihara M, Mimura C, Matsumiya W, Nakamura M. A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer. Am J Ophthalmol Case Rep. 2021 Mar 12;22:101072.

Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T, Legras A, Breadner D, Ricciuti B, Divisi D, Schmid RA, Peng RW, Yang H, Yao F. Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Transl Lung Cancer Res. 2021 Apr;10(4):1857-1872.

Nakajima T, Nagano T, Nishimura Y. Retrospective Study of the Effects of Post-nasal Drip Symptoms on Cough Duration. In Vivo. 2021 May-Jun;35(3):1799-1803.

Katsurada M, Nagano T, Nakajima T, Yasuda Y, Miwa N, Sekiya R, Kobayashi K, Hojo D, Nishimura Y. Retrospective analysis of the effect of inhaler education on improvements in inhaler usage. Respir Investig. 2021 May;59(3):312-319.

Bai S, Tian T, Pacheco JM, Tachihara M, Hu P, Zhang J. Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. Transl Lung Cancer Res. 2021 Jun;10(6):2614-2624.

Kim YH, Nishimura Y, Funada Y. How should we manage non-small-cell lung cancer "not-otherwise-specified"? Med Oncol. 2021 Jun 12;38(7):82.

Takemura T, Kataoka Y, Shirakawa C, Okazaki K, Sakurai A, Imakita T, Ikegaki S, Matsumoto H, Saito E, Takata H, Kaku S, Wada N, Shinomiya M, Otoshi T, Shimada M, Nikaido J, Iki R, Hirano K, Hirai T, Endo K, Hirabayashi M, Naganuma T Influence of loneliness and social isolation on the diagnosis and treatment of Japanese patients with advanced lung cancer: a prospective cohort study. Ann Palliat Med. 2021 Jun 10(6):6236-6246.

Furukawa K, Tjan LH, Sutandhio S, Kurahashi Y, Iwata S, Tohma Y, Sano S, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. Open Forum Infect Dis. 2021;8(10):ofab430.

Effendi WI, Nagano T. The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases. Int J Mol Sci. 2021 Sep 28;22(19):10447.

Hayashi H, Sugawara S, Fukuda Y, Sato Y, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Hosokawa S, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, NakagawaK.A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Lung Cancer. 2022;28(5):893-902.

Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Okamoto I, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira K, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K. Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Manag Res. 2021;13:9167-9173.

Yoshizaki A, Nagano T, Izumi S, Nishiuma T, Nakata K, Yamamoto M, Yasuda Y, Hazama D, Umezawa K, Katsurada N, Tachihara M, Nishimura Y, Kobayashi K. Characteristics of the nocturnal desaturation waveform pattern of SpO2 in COPD patients: an observational study. Respiratory Research. 2021 Oct 26;22(1):276.

Takanori Enomoto, Reina Sekiya, Hiroshi Sugimoto, Tomomi Terashita, Junya Yoshioka, Tatsuya Nagano, Yoshihiro Nishimura, Erika Yano, Tatsuya Moriyama, Kyosuke Nakata A case of hypersensitivity pneumonitis caused by Grey parrot (Psittacus erithacus) Internal Medicine, 2021 Dec 28. doi: 10.2169/internalmedicine.8679-21. Online ahead of print.

Otoshi T, Nagano T, Izumi S, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Kobayashi K, Nishimura Y A novel automatic cough frequency monitoring system combining a triaxial accelerometer and a stretchable strain sensor. Sci Rep. 2021;11:9937

Ouchi A, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Re-thinking about prophylactic cranial irradiation for small cell lung cancer in the MRI era. J Thorac Dis. 2021 Aug;13(8):5115-5116.

Otoshi T, Nagano T, Murakami S, Omori T, Hazama D, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y, Kobayashi K A randomized crossover pilot study comparing the efficacy of an auto-demand oxygen delivery system with that of a conventional demand oxygen delivery system in patients with chronic respiratory failure. Medicine (Baltimore). 2021 Sep 17; 100(37):e27191

Yamaoka T, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation. J Thorac Oncol. 2021 Sep;16(9):e71-e72.

Katsurada N, Tachihara M, Jimbo N, Yamamoto M, Yoshioka J, Mimura C, Satoh H, Furukawa K, Otoshi T, Kiriu T, Yasuda Y, Tanaka T, Nagano T, Nishimura Y. Yield of tumor samples with a large guide-sheath in endobronchial ultrasound transbronchial biopsy for non-small cell lung cancer: A prospective study. PLoS One. 2021 Oct 29;16(10):e0259236.

Yamasaki N, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021 Oct 2:S1525-7304(21)00249-7

Suraya R, Nagano T, Katsurada M, Sekiya R, Kobayashi K, Nishimura Y. Molecular mechanism of asthma and its novel molecular target therapeutic agent. Respir Investig. 2021; 59:291-301

Effendi WI, Nagano T. The Hedgehog Signaling Pathway in Idiopathic Pulmonary Fibrosis: Resurrection Time. Int J Mol Sci. 2021; 23:171

Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, Itoh S, Uemura T, Morinaga R, Takahama T, Nakashima K, Tachihara M, Saito G, Tanizaki J, Otsubo K, Ikeda S, Matsumoto H, Hara S, Hata A, Masuda T, Yamamoto N. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clin Res Rep. 2021;3(2):100265.

Megasari NLA, Utsumi T, Yamani LN, Juniastut, Gunawan E, Furukawa K, Nishimura M, Lusida MI, Mori Y. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. PLoS One. 2021 May 6;16(5):e0251234.

Nakajima T, Nagano T, Hojo D, Nishimura Y. An Investigation on the Consciousness of Patients and Pharmacists Regarding Inhaler Education. Kobe J Med Sci. 2021 67:E119-E124

Nagase H, Nishimura Y, Matsumoto H, Sugimoto N, Iwanaga T, Sano A, Konno S, Hizawa N, Asano K, Horiguchi T, Yokoyama A; Japanese Respiratory Society, Scientific Assembly for Allergy, Immunology, and Inflammation. The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. Respir Investig. 2021 59 :679-682.

Kitazawa H, Hizawa N, Nishimura Y, Fujisawa T, Iwanaga T, Sano A, Nagase H, Matsumoto H, Horiguchi T, Konno S, Asano K. The impact of the COVID-19 pandemic on asthma treatment in Japan: Perspectives based on doctors' views. Respir Investig. 2021 59:670-674.

(総説)アレルギー用語解説シリーズ　アトピー咳嗽　
安田裕一郎、永野達也
アレルギー、第70巻１号、Page46-47

(総説)ハウスダストマイト誘導性喘息マウスモデルにおける自然免疫系のかかわり　　
安田裕一郎、永野達也、西村善博
臨床免疫・アレルギー科、第75巻3号、Page348-354

気管支鏡検査で診断した神経鞘腫の2例
吉岡潤哉、立原素子、桐生辰徳、高田尚哉、梅澤佳乃子、桂田雅大、桂田直子、山本正嗣、西村善博
気管支学43(2): 168-174, 2021

日本呼吸器学会会員における大学院進学に関する最近の動向
髙橋　浩一郎，小林　信明，浅井　一久，礒部　威，今泉　和良，大平　徹郎，長内　忍，川山　智隆，國近　尚美，小林　和幸，佐野　博幸，多賀谷悦子，千葉　弘文，橋本　直純，須田　隆文，金子　猛
日呼吸誌, 10(3): 207-211, 2021

(総説)アレルギー用語解説シリーズ　好酸球性多発血管炎性肉芽腫症;EGPA
福井崇文，永野達也，西村善博
第70巻10号、Page 1398-1399

(総説)夏場に多い過敏性肺炎とは
西村善博
健康教室　2021年　第72巻　第8号

(総説)気管支喘息の分子機序
永野達也、西村善博
医学と薬学　2021年　第78巻　第12号　Page1505-1509

(書籍)過敏性肺炎
西村善博
私の治療2021-22年度版、猿田享男、北村惣一朗編、日本医事新報社、2021、214

(書籍)副腎皮質ステロイド薬
西村善博
呼吸器疾患最新の治療2021－2022、門田淳一、弦間昭彦、西岡安彦編　南江堂　2021，85-87

(書籍)生物学的製剤（抗IgE抗体薬、抗IL-5抗体を含む）
西村善博
呼吸器専門医テキスト　改訂版２版　日本呼吸器学会編　2020、204-206

(書籍)オシメルチニブ、ゲフィチニブ
立原素子
がんロコモハンドブック　総合医学社　2021年10月

(書籍)新型コロナウイルスに対する抗体調査
古川皓一、森康子
大阪大学医学部学友会会誌 2021 Vol.41, 97-100

Yoshizaki A, Yamamoto M, Hirabayashi A, Ono Y, Hatakeyama Y, Nakata K,
Tamura D, Tachihara M, Kamiryo H, Kobayashi K, Nsihio M, Nishimura Y.
Fatal Hemoptysis Due to Endobronchial Aspergilloma in the Hyperinflated Native Lung after Single-Lung Transplantation for Lymphangioleiomyomatosis: A Case Report
Kobe Journal of Medical Sciences 2020 Jan 20;65(4):E114-E117

Katsurada N, Tachihara M, Hatakeyama Y, Koyama K, Yumura,M, Kiriu T, Dokuni R, Hazama D, Tokunaga S, Tamura D, Nakata K, Yamamoto M, Kamiryo H, Kobayashi K, Tanaka Y, Maniwa Y, NishimuraY.
Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC.
Cancer Manag Res. 2020; 12: 777782. 

Nagano T, Tachihara M, Hazama D, Nishimura Y. Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer. J Thorac Dis, 2020 Aug;12(8):4561-4563.

Tachihara M, Dokuni R, Okuno K, Tokunaga S, Nakata K, Katsurada N, Yamamoto M, Nagano T, Kobayashi K, Tanaka Y, Funada Y, Maniwa Y, Nishimura Y. Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer. Thorac Cancer. 2020 Sep;11(9):2536-2541.

Suraya R, Nagano T, Kobayashi K, Nishimura Y. Microbiome as a Target for Cancer Therapy. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420920721.

Sekiya R, Nagano T, Moriyama T, Kishi T, Shinke H, Yano E, Hatano N, Katsurada M, Umezawa K, Katsurada N, Hori S, Hazeki N, Fukunaga A, Yamamoto M, Kamiryo H, Shinohara M, Kobayashi K, Kotani Y, Nishimura Y. Occupational respiratory allergy to lettuce in lettuce farmers. Clin Exp Allergy. 2020 Jun 15. doi: 10.1111/cea.13682.

Nagano T, Arii J, Nishimura M, Yoshida N, Iida K, Nishimura Y, Mori Y. Diligent medical activities of a publicly designated medical institution for infectious diseases pave the way for overcoming COVID-19: A positive message to people working at the cutting edge. Clin Infect Dis. 2020 May 31:ciaa694. doi: 10.1093/cid/ciaa694.

Effendi WI, Nagano T, Hasan H, Yudhawati R. Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases. Int J Mol Sci. 2020 May 22;21(10):3665.

Yasuda Y, Nagano T, Kobayashi K, Nishimura Y. Group 2 Innate Lymphoid Cells and the House Dust Mite-Induced Asthma Mouse Model. Cells. 2020 May 9;9(5):1178.

Nagano T, Kobayashi K, Omori T, Otoshi T, Umezawa K, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y. Randomized cross-over trial of demand oxygen delivery system in nocturnal hypoxemia. Medicine (Baltimore). 2020 May;99(19):e20031.

Nagano T, Kobayashi K, Omori T, Otoshi T, Umezawa K, Katsurada N, Yamamoto M, Tachihara M, Nishimura Y. Randomized cross-over trial of demand oxygen delivery system. Medicine (Baltimore). 2020 May;99(19):e20010.

Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases. Cells. 2020 Mar 24;9(3):785.

Ikegaki S, Otoshi T, Hirai T, Hirabayashi M. A rare case of parathyroid crisis with respiratory failure successfully treated using extracorporeal membrane oxygenation. Respir Med Case Rep. 2020 May 11;30:101088.

Sato H, Tachihara M, Kiriu T, Yamamoto M, Tanaka Y, Nishimura Y. Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy. Respirol Case Rep. 2020;8(6):e00618.

Shiraishi Y, Kishimoto J, Tanaka K, Sugawara S, Daga H, Hirano K, Azuma K, Hataji O, Hayashi H, Tachihara M, Mitsudomi T, Seto T, Nakagawa K, Yamamoto N, Okamoto I.Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 Apr 10:S1525-7304(20)30089-9.

Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I. A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).　Cancer. 2020 ;126(16):3648-3656.

Hazama D, Yin Y, Murata Y, Matsuda M, Okamoto T, Tanaka D, Terasaka N, Zhao J, Sakamoto M, Kakuchi Y, Saito Y, Kotani T, Nishimura Y, Nakagawa A, Suga H, Matozaki T. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy. Cell Chem Biol. 2020 Jul 1:S2451-9456(20)30231-2.

Masako Y, Taysuya N, Yoshihiro N. Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. Molecules 2020 July 25(17), 3987.

Nagano T, Tachihara M, Hazama D, Nishimura Y. Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer. J Thorac Dis. 2020 Aug;12(8):4561-4563.

Miwa N, Nagano T, Jimbo N, Dokuni R, Kiriu T, Mimura C, Yasuda Y, Katsurada M, Yamamoto M, Tachihara M, Tanaka Y, Kobayashi K, Itoh T, Maniwa Y, Nishimura Y. Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma. Onco Targets Ther. 2020 Sep 10;13:9005-9013.

Hazama D, Yin Y, Murata Y, Matsuda M, Okamoto T, Tanaka D, Terasaka N, Zhao J, Sakamoto M, Kakuchi Y, Saito Y, Kotani T, Nishimura Y, Nakagawa A, Suga H, Matozaki T. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy. Cell Chem Biol. 2020 Sep 17;27(9):1181-1191.

Furukawa K, Nagano T, Tachihara M, Yamamoto M, Nishimura Y.　Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. Molecules. 2020 Aug 26;25(17):3900.

Nakajima T, Nagano T, Suraya R, Kawafune Y, Hojo D, Kato H, Nishimura Y. A Questionnaire Survey of the Inhalation Instruction in Pharmacies. Kobe J Med Sci. 2020 Nov 17;66(3):E113-E118.

Dokuni R, Nagano T, Jimbo N, Sato H, Kiriu T, Yasuda Y, Yamamoto M, Tachihara M, Kobayashi K, Maniwa Y, Nishimura Y. High expression level of serpin peptidase inhibitor clade E member 2 is associated with poor prognosis in lung adenocarcinoma. Respir Res. 2020 Dec 14;21(1):331.

呼吸器内科医師の海外留学に関するアンケート調査
小林信明，髙橋浩一郎，浅井一久，礒部威，今泉和良，大平徹郎，長内忍，川山智隆，國近尚美，小林和幸，佐野博幸，多賀谷悦子，千葉弘文，橋本直純，須田隆文，金子猛
日呼吸誌, 10(2): 102-107, 2021

多発脳腫瘍に対し血漿検査で診断しオシメルチニブによる治療効果が得られた1例
三村　千尋、山本　正嗣、行田　まな、藤岡　美結、小山　貴代子、湯村　真沙子、寺下　智美、桂田　直子、梅澤　佳乃子、立原　素子、小林　和幸、西村　善博
癌と化学療法　第48巻第5号（5月号）に掲載予定

呼吸器症状の鑑別におけるモストグラフの有用性についての検討
西馬 照明, 堀 朱矢, 徳永 俊太郎, 藤井 真央, 石田 貢一, 山本 賢, 西村 善博
アレルギーの臨床 40巻7号 Page579-582, 2020

ヒト化抗インターロイキン-5受容体αモノクローナル抗体製剤ベンラリズマブの特定使用成績調査　中間報告
西村 善博, 山口 正雄, 堀田 麻里子, 林 暢哉, 坂本 慶, 時本 敏充, 東田 有智
Therapeutic Research 41巻9号 Page747-759, 2020

(総説) 医療介護関連肺炎 (NHCAP)の治療
桂田直子 medicina 57巻: 62-65項, 2020年

(総説) Resident eosinophils
堂國良太、西村善博
アレルギー、第69巻1号、Page61

(総説) 治療法の再整理とアップデートのために　専門家による私の治療　過敏性肺炎
西村 善博
日本医事新報5002号 Page38, 2020年

(総説) アレルギー用語解説シリーズ　Resident eosinophils
堂國良太、西村善博
アレルギー、第69巻1号、Page61, 2020

(総説) アレルギー用語解説シリーズ　好塩基球活性化試験(BAT)
吉岡潤哉、西村善博
アレルギー 第69巻8号 Page710-711, 2020

(書籍) 遷延性咳嗽
西村善博
今日の治療指針2020　福井次矢、高木誠、小室一成編　医学書院　295-297, 2020

(書籍) アレルギー性気管支肺真菌症
西村善博
今日の治療指針2020　福井次矢、高木誠、小室一成編　医学書院　843-845, 2020

(書籍) PD-L1について
遺伝子変異パネル検査
デュルバルマブ
立原素子　
肺癌診療 虎の巻 WJOG 肺がんグループのプラクティス 監修　山本信之　クリニコ出版

Tachihara M, Kiriu T, Hata A, Hatakeyama Y, Nakata K, Nagano T,
Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y.
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Cancer Manag Res. 2019 Jul 29;11:7135-7140.

Katsurada N, Nishimura Y.
Viral pneumonia: which patients should we focus on?
Infect Dis (Lond). 2019 Jul;51(7):510-511.

Murakami S, Nagano T, Nakata K, Onishi A, Umezawa K, Katsurada N, Yamamoto M,
Tachihara M, Kobayashi K, Nishimura Y.
Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
Intern Med. 2019 Oct 1;58(19):2839-2843.

Tachihara M, Nishimura Y.
Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
J Thorac Dis. 2019 May;11(Suppl 9):S1289-S1291.

Katsurada N, Ohnishi H, Ikeda M, Jimbo N, Hatakeyama Y, Okamura K.
Primary pleural synovial sarcoma with repeated resection leading to long-term survival.
Respirol Case Rep. 2019 Aug 20;7(8):e00480.

Nagano T, Katsurada M, Dokuni R, Hazama D, Kiriu T, Umezawa K, Kobayashi K, Nishimura Y.
Crucial Role of Extracellular Vesicles in Bronchial Asthma.
Int J Mol Sci. 2019 May 27;20(10). pii: E2589.

Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, Nishimura Y.
Novel cancer therapy targeting microbiome.
Onco Targets Ther. 2019 May 13;12:3619-3624.

Effendi WI, Nagano T, Tachihara M, Umezawa K, Kiriu T, Dokuni R, Katsurada M, Yamamoto M,
Kobayashi K, Nishimura Y.
Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines.
Cancer Manag Res. 2019 Apr 29;11:3669-3679.

Nagano T, Katsurada M, Yasuda Y, Kobayashi K, Nishimura Y.
Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials.
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619875925.

Nagano T, Tachihara M, Nishimura Y.
Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Drugs Today (Barc). 2019 Apr;55(4):231-236.

Otoshi T, Nagano T, Tachihara M, Nishimura Y.
Possible Biomarkers for Cancer Immunotherapy.
Cancers (Basel). 2019 Jul 3;11(7). pii: E935.

Koyama K, Katsurada N, Jimbo N, Tachihara M, Tamura D, Nakata K, Nagano T,
Yamamoto M, Kamiryo H, Kobayashi K, Itoh T, Nishimura Y.
Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Pathol Int. 2019 May;69(5):294-299.

Yasuda Y, Nagano T, Tachihara M, Chihara N, Umezawa K, Katsurada N, Yamamoto M,
Sekiguchi K, Kobayashi K, Nishimura Y.
Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review
Ther Clin Risk Manag 2019 in press

Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K.
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).
Clin Lung Cancer. 2019 Jul;20(4):e492-e494.

Chayahara N, Mukohara T, Tachihara M, Fujishima Y, Fukunaga A, Washio K, Yamamoto M, Nakata K,
Kobayashi K, Takenaka K, Toyoda M, Kiyota N, Tobimatsu K, Doi H, Mizuta N, Marugami N, Kawaguchi A,
Nishigori C, Nishimura Y, Minami H.
Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Oncologist. 2019 Jul;24(7):885-e413.

Kiriu T, Yamamoto M, Nagano T, Koyama K, Katsurada M, Tamura D, Nakata K,
Tachihara M, Kobayashi K, Nishimura Y.
Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody
In Vivo. 2019 Jan-Feb;33(1):213-220. doi: 10.21873/invivo.11462.

Katsurada M, Nagano T, Tachihara M, Kiriu T, Furukawa K, Koyama K, Otoshi T, Sekiya R, Hazama D,
Tamura D, Nakata K, Katsurada N, Yamamoto M, Kobayashi K, Nishimura Y.
Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
Anticancer Res. 2019 Feb;39(2):815-825. doi: 10.21873/anticanres.13180.

Katsurada N, Tachihara M, Jimbo N, Koyama K, Nakata K, Nagano T, Yamamoto M, Kamiryo H,
Kobayashi K, Nishimura Y.
Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy: A Case Report.
Intern Med. 2019 Jan 10 doi: 10.2169/internalmedicine.1982-18

Umezawa K, Nagano T, Kobayashi K, Dokuni R, Katsurada M, Yamamoto M, Yoshikawa Y, Kataoka T, Nishimura Y.
Phospholipase Cε plays a crucial role in　neutrophilic inflammation accompanying　acute lung injury through augmentation of　CXC chemokine production from alveolar　epithelial cells
Respiratory Research. 2019;20(9).

Tachihara M, Yamamoto M, Yumura M, Yoshizaki A, Kobayashi K, Nishimura Y.
Non-parallel anti-tumour effects of pembrolizumab: a case of cardial tamponade.
Respirol Case Rep. 2019 Jan 31;7(3):e00404.

Otoshi T, Nagano T, Funada Y, Takenaka K, Nakata H, Ohnishi H, Nishiuma T, Nakajima T,
Kageshita T, Tsuchiya T, Yamamoto M, Kobayashi K, Nishimura Y.
A Cross-sectional Survey of the Clinical Manifestations and Underlying Illness of Cough.
In Vivo. 2019 Mar-Apr;33(2):543-549.

Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K.
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).Clin Lung Cancer. 2019 Jul;20(4):e492-e494.

Chayahara N, Mukohara T, Tachihara M, Fujishima Y, Fukunaga A, Washio K, Yamamoto M, Nakata K, Kobayashi K, Takenaka K, Toyoda M, Kiyota N, Tobimatsu K, Doi H, Mizuta N, Marugami N, Kawaguchi A, Nishigori C, Nishimura Y, Minami H.
Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).Oncologist. 2019 Jul;24(7):885-e413.

Izumi S, Nagano T, Yoshizaki A, Nishimura Y.
Classification Algorithm for Nocturnal Hypoxemia Using Nocturnal Pulse Oximetry.
Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:3662-3665

Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Katsurada N, Tachihara M, Kobayashi K, Nishimura Y.
Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case-Control Study.
Onco Targets Ther. 2019 Dec 2;12:10559-10568.

尿毒症性胸膜炎患者における局所麻酔下胸腔鏡検査による胸膜病変の検討
梅澤 佳乃子, 大西 尚, 湯村 真沙子, 藤井 真央, 𠮷﨑 飛鳥, 川本 めぐみ, 尾野 慶彦, 堂國 良太, 吉村 将
気管支学 41(3):233-238,2019

抗ヒトIL-17RAモノクローナル抗体ブロダルマブを投与後に胸膜炎，大動脈炎を発症した膿疱性乾癬の1例
吉岡　愛育、福永　淳、横山　大輔、大幡　万里恵、桂田　雅大、明石 健吾、錦織 千佳子
臨床皮膚科　73(11):887-892,2019

局所麻酔下胸腔鏡下生検で診断した肺癌肉腫の芽腫様亜型の1例
堂國 良太, 立原 素子, 田村 大介, 中田 恭介, 堀 朱矢, 山本 正嗣, 上領 博, 小林 和幸, 西村 善博
気管支学 41(1):40-45,2019

(総説) 免疫関連有害事象（immune-related Adverse Events）
古川　皓一、西村善博
アレルギー　第68巻　in press

(総説) エンドタイプ
永野達也、西村善博
アレルギー、第68巻8号、Page970

(書籍)咳喘息とアトピー咳嗽
西村善博
今日の治療指針2019　福井次矢、高木誠、小室一成編　医学書院　825-827, 2019

(書籍)肺がん化学療法 副作用マネジメント プロのコツ 単行本 – 2019/7/22
立原素子
倉田宝保、吉岡弘鎮、金田俊彦 編

Nagano T, Tachihara M, Nishimura Y.
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Curr Cancer Drug Targets. 2018 Dec 9. doi: 10.2174/1568009619666181210114559.

Nagano T, Tachihara M, Nishimura Y.
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells. 2018 Nov 15;7(11). pii: E212. doi: 10.3390/cells7110212.

Kiriu T, Tamura D, Tachihara M, Sekiya R, Hazama D, Katsurada M, Nakata K,
Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Nishimura Y.
Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease: A Case Report
Intern Med. 2018 Jan 1;57(1):91-95.

Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Tamura D,
Tachihara M, Kobayashi K, Nishimura Y.
The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer
PLoS One. 2018 Feb 15;13(2):e0193018

Yasuda Y, Hattori Y, Tohnai R, Ito S, Kawa Y, Kono Y, Urata Y,
Nogami M, Takenaka D, Negoro S, Satouchi M.
The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease
Jpn J Clin Oncol. 2018 Jan 1;48(1):89-93.

Kojima M, Nagano T, Nakata K, Hara S, Katsurada N, Yamamoto M, Tachihara M,
Kamiryo H, Kobayashi K, Usui T, Nishimura Y.
Lung squamous cell carcinoma associated with HDR syndrome: a case report
Onco Targets Ther. 2018 in press.

Nagano T, Tachihara M, Nishimura Y.
Does ipilimumab show an increased clinical benefit when combined in sequence with chemotherapy?
Transl Cancer Res. 2018 in press.

Murata Y, Tanaka D, Hazama D, Yanagita T, Saito Y, Kotani T, Oldenborg PA, Matozaki T.
Anti-human SIRPα antibody is a new tool for cancer immunotherapy
Cancer Sci. 2018 Feb 23.

Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, Irie K, Okada H, Fukushima S, Katakami N.
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
Br J Cancer. 2018 Jan;118(1):32-37

Yasuda Y, Urata Y, Tohnai R, Ito S, Kawa Y, Kono Y, Hattori Y, Tsuda M, Sakuma T, Negoro S, Satouchi M.
Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Intern Med. 2018 May 1;57(9):1269-1272.

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, and Negoro S on behalf of HANSHIN Oncology Group
Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter Single Arm Phase II Trial (ABC-Study)
Cancer. 2018 in press

Tachihara M, Tamura D, Kiriu T, Tokunaga S, Hatakeyama Y, Shinke H, Nagano T, Nakata K, Hazeki N, Kamiryo H, Kobayashi K, Nishimura Y.
Bronchoscopy Using Virtual Navigation and Endobronchial Ultrasonography with a Guide Sheath (EBUS-GS) with or without Fluoroscopy for Peripheral Pulmonary Lesions.
Kobe J Med Sci. 2018 Mar 27;63(4):E99-E104.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M,
Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
Lung Cancer. 2018 124:65-70

Yoichiro Sugizaki, Shumpei Mori, Yuichi Nagamatsu, Tomomi Akita, Akira Nagasawa, Takayoshi Toba, Masatsugu Yamamoto, Tatsuya Nishii, Norihiko Obata, Yoshikatsu Nomura, Hiromasa Otake, Toshiro Shinke, Yutaka Okita, Ken-ichi Hirata,
Critical exacerbation of idiopathic pulmonary fibrosis after transcatheter aortic valve implantation: Need for multidisciplinary care beyond “heart team”,
Journal of Cardiology Cases, 2018, in press

Suzuki M, Katsurada N, Le MN, Kaneko N, Yaegashi M, Hosokawa N, Otsuka Y, Aoshima M, Yoshida LM, Morimoto K.
Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan.
Vaccine. 2018 May 17;36(21):2960-2967.

Kishida Y, Seki S, Yoshikawa T, Itoh T, Maniwa Y, Nishimura Y, Ohno Y.
Performance Comparison Between 18F-FDG PET/CT Plus Brain MRI and Conventional Staging Plus Brain MRI in Staging of Small Cell Lung Carcinoma.
AJR Am J Roentgenol. 2018 Jul;211(1):185-192.

Tachihara M; Syunichi Negoro; Takako Inoue; Motohiro Tamiya; Yuki Akazawa; Takeshi Uenami;
Yoshiko Urata; Yoshihiro Hattori; Akito Hata; Nobuyuki Katakami; Soichiro Yokota.
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
BMC cancer in press.

Ogawa H, Tanaka Y, Tachihara M, Uehara K, Shimizu N, Doi T, Hokka D, Maniwa Y.
ROS1-rearranged PD-L1 High-expression Lung Adenocarcinoma Manifesting as Mediastinal Tumor.
ONCOLOGY LETTERS. in press

Kawa Y, Nagano T, Yoshizaki A, Dokuni R, Katsurada M, Terashita T, Yasuda Y, Umezawa K, Yamamoto M, Kamiryo H, Kobayashi K, Nishimura Y.
Role of S1P/S1PR3 axis in release of CCL20 from human bronchial epithelial cells.
PLoS One. 2018 Sep 7;13(9):e0203211.

Miwa N, Nagano T, Ohnishi H, Nishiuma T, Takenaka K, Shirotani T, Nakajima T, Dokuni R, Kawa Y, Kobayashi K, Funada Y, Kotani K, Nishimura Y.
An Open-Label, Multi-Institutional, Randomized Study to Evaluate the Additive Effect of a Leukotriene Receptor Antagonist on Cough Score in Patients with Cough-Variant Asthma Being Treated with Inhaled Corticosteroids
Kobe J Med Sci. 2018 in press

経気管支針生検にて術前診断しえた炎症性筋線維芽細胞腫の1例
寺下智美，立原素子，堂國良太，吉崎飛鳥，関谷怜奈，田村大介，山本正嗣，
上領博，小林和幸，西村善博
気管支学 40(2):163-167,2018

抗インターフェロン-γ自己抗体陽性の播種性M. colombiense症の1例
尾野慶彦，山本正嗣，小濱みずき，吉崎飛鳥，小林和幸，西村善博
日呼吸誌, 7(3): 166-170, 2018

（総説）COPD慢性期治療
桂田直子・西村善博
medicina 55 (1): 106-108, 2018

（総説）ICS、ICS/LABAの使い方
湯村真沙子、西村善博
アレルギーの臨床　38(4),2018 in press.

【診断と治療のABC[140]慢性閉塞性肺疾患(COPD)】 (第4章)管理・治療　COPDの医療経済(解説/特集)
桂田雅大・西村善博
最新医学 (0370-8241)別冊慢性閉塞性肺疾患(COPD) Page219-227(2018.11)

(総説)咳喘息
三輪菜々子、西村善博
アレルギー　67(9),1281-1282,2018

(総説)COPDの呼吸生理検査の方向性‐最新のCOPD実地診療のポイント整理と活用
関谷怜奈、西村善博
Medical Practice　 35 (8) 1227-1231,2018

Hazeki N, Tachihara M, Tsukamoto R, Tokunaga S, Tamura D,
Shinke H, Kobayashi K, Sakai Y, Nishimura Y.
Utility of cell blocks obtained by catheter aspiration via
a guide sheath during endobronchial ultrasonography.
Respir Investig. 2017;55(2):161-165.

Tohda Y, Iwanaga T, Sano H, Kume H, Hirata K, Ohkura N, Tachibana I,
Nishimura Y, Matsumoto H, Minakata Y, Yoshikawa M, Fujimura M;
Kansai and Hokuriku Academy for Asthma Treatment.
Improved quality of life in asthma patients under long-term therapy:
Assessed by AHQ-Japan.
Int J Clin Pract. 2017;71(1). doi: 10.1111/ijcp.12898. Epub 2016 Dec 9.

Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M,
Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M,
Sakai H, Goto K, Yamamoto N.
Prophylactic cranial irradiation versus observation in patients with extensive-disease
small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. 2017 May;18(5):663-671.

Kunimasa K, Nagano T, Shimono Y, Dokuni R, Kiriu T, Tokunaga S, Tamura D,
Yamamoto M, Tachihara M, Kobayashi K, Satouchi M, Nishimura Y.
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal
growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Cancer Sci. 2017;108(7):1368-1377.

Tokunaga S, Nagano T, Kobayashi K, Katsurada M, Nakata K, Yamamoto M,
Tachihara M, Kamiryo H, Yokozaki H, Nishimura Y.
Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
Anticancer Res. 2017;37(5):2225-2231.

Yanagita T, Murata Y, Tanaka D, Motegi SI, Arai E, Daniwijaya EW, Hazama D, Washio K, Saito Y,
Kotani T, Ohnishi H, Oldenborg PA, Garcia NV, Miyasaka M, Ishikawa O, Kanai Y, Komori T, Matozaki T.
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy
JCI Insight. 2017 Jan 12;2(1):e89140.

Tachihara M, Tanaka Y, Zen Y, Nishimura Y.
The Notable Appearance of Pulmonary Artery Intimal Sarcoma on Positron Emission Tomography (PET)/CT
Intern Med. 2017 Nov 1;56(21):2953-2954.

Katsurada N, Suzuki M, Aoshima M, Yaegashi M, Ishifuji T, Asoh N, Hamashige N, Abe M,
Ariyoshi K, Morimoto K; Adult Pneumonia Study Group-Japan.
The impact of virus infections on pneumonia mortality is complex in adults: a prospective multicentre observational study
BMC Infect Dis. 2017 Dec 6;17(1):755.

Oki T, Tanaka H, Imanishi T, Nakamachi Y, Saegusa J, Kawano S, Hirata KI, Nishimura Y.
Associations between left ventricular diastolic function and right ventricular function in patients with and without preserved left ventricular ejection fraction
Intern Med. 2017 Dec 15;56(24):3333-3339. doi: 10.2169/internalmedicine.6754-15. Epub 2017 Oct 11.

Hori S, Tachihara M, Tamura D, Kobayashi K, Nakata K, Kamiryo H, Sakai Y, Itoh T, Hirose T, Nishimura Y.
Spontaneous Regression of Epithelioid Angiosarcoma in a Young Woman.
J Echocardiogr. 2017 Dec 11. doi: 10.1007/s12574-017-0363-3. [Epub ahead of print]

(Book) Katsurada M, Izumo T. (2017).
Chapter 9 Anesthesia for Bronchoscopy.
Izumo T, Sasada S, Aso T, Nasu K, Arai Y. (Eds.) Respiratory Endoscopy.
Singapore: Springer, pp. 53-58.

(Book) Katsurada M, Izumo T. (2017).
Chapter 22 The Dose and Risk Factors for Radiation Exposure from X-Ray
Fluoroscopy During EBUS-GS for Peripheral Pulmonary Lesions.
Izumo T, Sasada S, Aso T, Nasu K, Arai Y. (Eds.) Respiratory Endoscopy.
Singapore: Springer, pp. 53-58.

経気管支肺生検で診断しえた異所性石灰化症の長期経過観察例
羽間大祐, 立原素子, 國政啓, 堂國良太, 桐生辰徳, 田村大介,
櫨木暢子, 上領博, 小林和幸, 西村善博
気管支学39巻1号 Page64-70, 2017

成人T細胞白血病リンパ腫の診断にセルブロックが有用であった1例
山本正嗣、里内美弥子、高瀬直人、伊藤彰一、河良崇、河野祐子、
浦田佳子、島田天美子、服部剛弘、根來 俊一
気管支学39巻2号 Page165-169, 2017

急性呼吸不全を呈した抗OJ抗体の1例
関谷怜奈、西尾智尋、冨岡洋海、山下修司
日呼吸誌6 (4):235-239,2017

救急病院における喘息患者の治療実態アンケート　兵庫県喘息死ゼロ作戦活動報告2013
堀 朱矢、上領 博、新家治子、櫨木暢子、小林和幸、片山 覚、西村善博
臨床免疫・アレルギー科 68(1): 107-114, 2017

(総説)職業関連呼吸器疾患　じん肺,悪性胸膜中皮腫を中心に概観する
桂田雅大、西村善博
Hospitalist 5巻2号,291-301 2017

(総説)再生検の現状と課題（リキッドバイオプシーを含めて）
安田裕一郎、里内美弥子
日本臨牀 75(7): 1121-1127, 2017

（総説）リキッドバイオプシー
安田裕一郎、里内美弥子
診断と治療 105(11): 1451-1455, 2017.

(書籍)肺がん（12 肺がんの治療 4高齢者肺がんに対する治療 ①非小細胞がん）
山本正嗣　里内美弥子
インフォームドコンセントのための図説シリーズ改訂5版、2017年

(書籍)胸郭の異常（漏斗胸・鳩胸）
西村善博
内科学第11版　矢先義雄編　朝倉書店　861-862, 2017

Koyama H, Ohno Y, Fujisawa Y, Seki S, Negi N, Murakami T, Yoshikawa T,
Sugihara N, Nishimura Y, Sugimura K.
3D lung motion assessments on inspiratory/expiratory thin-section CT:
Capability for pulmonary functional loss of smoking-related COPD in
comparison with lung destruction and air trapping.
Eur J Radiol. 2016 85(2):352-9.

Kunimasa K, Kobayashi K, Inoue N, Nishimura Y.
Haemoptysis as a Presenting Symptom of Thoracic Aneurysm Dissection.
Intern Med. 2016;55(15):2117-8.

Kunimasa K, Tachihara M, Tamura D, Tokunaga S, Nakata K, Hazeki N,
Kamiryo H, Kobayashi K, Sakai Y, Nishimura Y.
Diagnostic utility of additional conventional techniques after
endobronchial ultrasonography guidance during transbronchial biopsy.
Respirology. 2016;21(6):1100-5.

Fukuhara N, Tachihara M, Tanino Y, Saito J, Sato S, Nikaido T, Misa K,
Fukuhara A, Wang X, Ishida T, Onami T, Munakata M.
Cholesteryl palmitate crystals in bronchoalveolar lavage fluid smears as
a possible prognostic biomarker for chronic interstitial pneumonia: A
preliminary study.
Respir Investig. 2016;54(2):109-15.

Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T,
Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S,
Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.　
Detection of the T790M mutation of EGFR in plasma of advanced non-small
cell lung cancer patients with acquired resistance to tyrosine kinase
inhibitors (West Japan oncology group 8014LTR study).
Oncotarget. 2016;7(36):58492-58499.

Rider CF, Yamamoto M, Günther OP, Hirota JA, Singh A, Tebbutt SJ,
Carlsten C.
Controlled diesel exhaust and allergen coexposure modulates microRNA and
gene　expression in humans: Effects on inflammatory lung markers.
J Allergy Clin Immunol. 2016;138(6):1690-1700.

Takase N, Hattori Y, Kiriu T, Itoh S, Kawa Y, Yamamoto M,
Urata Y, Shimada T, Tsujino K, Soejima T, Negoro S, Satouchi M.
Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients
with stage III unresectable non-small cell lung cancer: A retrospective study.
Respir Investig. 2016;54(5):334-40.

Terashita T, Kobayashi K, Nagano T, Kawa Y, Tamura D, Nakata K,
Yamamoto M, Tachihara M, Kamiryo H, Nishimura Y.
Administration of JTE013 abrogates experimental asthma by regulating
proinflammatory cytokine production from bronchial epithelial cells.
Respir Res. 2016;17(1):146.

Allergic bronchopulmonary aspergillosis(ABPA)様の画像を呈した
ピーナッツ気管支異物の一例
関谷怜奈，小林和幸，堂國良太，羽間大祐，桐生辰徳，國政啓，田村大介，
立原素子,上領博，西村善博
気管支学38巻6号, 515-520, 2016

(総説)呼吸機能検査でできること
西村善博
呼吸器内科30巻4号, 342-348, 2016

(総説) 診断がつかないせき、対応に困るせき
桂田雅大、西村善博
JOHNS 32巻8号, 941-945, 2016

Asano F, Shinagawa N, Ishida T, Tsuzuku A, Tachihara M, Kanazawa K,
Yamada N, Oizumi S, Moriya H. Virtual Bronchoscopic Navigation Improves
the Diagnostic Yield of Radial-Endobronchial Ultrasound for Peripheral
Pulmonary Lesions with Involved Bronchi on CT.
Intern Med 2015；54: 1021-1025.

Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, KaJi R, Hata A, Hattori
Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S,
Morita S, Yokota S. Effectiveness of Tyrosine Kinase Inhibitors in
Japanese Patients with Non-small Cell Lung Cancer Harboring Minor
Epidermal Growth Factor Receptor Mutations: Results from a Multicenter
Retrospective Study (HANSHIN Oncology Group 0212).
Anticancer research 2015;35: 3885-3892.

Nishino K, Imamura F, Kumagaia T, Katakami N, Hata A, Okuda C, Urata Y,
Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M,
Morita S, Negoro S.
A randomized phase II study of bevacizumab in combination with docetaxel
or S-1 in patients with non-squamous non-small-cell lung
cancer previously treated with platinum based chemotherapy (HANSHIN
Oncology Group 0110).
Lung Cancer. 2015; 89 2015:146–153.

Okuma Y, Tanuma J, Kamiryo H, Kojima Y, Yotsumoto M, Ajisawa A, Uehira
T, Nagai H, Takeda Y, Setoguchi Y, Okada S.
A multi-institutional study of clinicopathological features and
molecular epidemiology of epidermal growth factor receptor mutations in
lung cancer patients living with human immunodeficiency virus infection.
J Cancer Res Clin Oncol. 2015 Mar 24.

Kunimasa K, Tachihara M, Terashita T, Nishimura Y
Gradually Enlarging Crazy-paving Appearance.
Intern Med. 2015;54(21):2791-2.

呼吸器抄読会　神戸大学大学院医学研究科内科学講座呼吸器内科学分野
呼吸　34巻1号、120、2015

COPD診療にいかに取り組むか　COPDの診断法と治療
西村善博
兵庫県医師会医学雑誌 第58巻1号 4-6，2015

喘息発作による救急外来受診後の再受診状況の現状と課題
櫨木暢子，小林和幸，船田泰弘，寺田忠之，中谷裕司，岡勝巳，金岡正樹，岸本信康，黒坂文武，田中明，西庵利彦，望月吉郎，八木一之，山田充宏，山本裕之，薄木洋明，大本明義，西村善博
兵庫県医師会医学雑誌　第58巻第1号 44-49，2015

Picture in Clinical
Hematology(No.85)　FDG-PETで両肺にびまん性異常集積を認めた血管内大細胞型B細胞リンパ腫.
阿部緑生，立原素子，植松学，勝浦豊，田中端子，杉野隆，小川一英.
臨床血液2015;56:749.

左上葉腫瘤に対する経気管支生検に加えて，右肺門リンパ節の経気管支穿刺吸引細胞診を行うことで診断し得た同時多発肺癌の1例
高瀬直人，里内美弥子，桐生辰徳，西村春佳，伊藤彰一，内堀健，山本正嗣，奥野恵子，浦田佳子，島田天美子，服部剛弘，根來俊一
気管支学 37巻5号，537-543，2015

気管支擦過細胞診にてアレルギー性気管支肺アスペルギルス症が疑われた1例
寺下智美，立原素子，上原慶一郎，酒井康裕，西村善博
臨床細胞学会，54巻，221-222，2015